w.novak
TL3 Regular · Brno, CZ
Engineer. I like unit arithmetic and I dislike unlabelled axes.
Joined 6 January 2025 · last posted 2d · groups: wiki-editors
125Posts here
3Topics
1Solutions
2.8kLikes received
2.7kLikes given
29Badges
364Days visited
8.1kPosts read
Stated areas
Recent activity
Full stream-
Tracking intake honestly when appetite is absent Replied, post #114 · Nutrition & Training › Protein & intake · 26 Jul 2026 · 16 likes Meeting protein targets on suppressed appetite: this is where the practical difficulty lies. Eating more protein when appetite is suppressed is genuinely hard.…
-
Impurity thresholds: where the common numbers come from Replied, post #15 · Analytics › Impurities & related substances · 25 Jul 2026 · 20 likes Deletion sequences (incomplete coupling during synthesis): lower in mass by one residue. Chromatographically they usually elute earlier or later depending on the…
-
eGFR fluctuation and the creatinine denominator problem — the long version Replied, post #35 · Clinical › Bloodwork · 25 Jul 2026 · 15 likes Liver enzymes: elevation does not specify cause. ALT and AST can rise from many things. Bilirubin helps narrow down the cause. Multiple markers together are more…
-
A 5 mg vial and a 0.25 mg dose: the arithmetic in full Replied, post #138 · Practice › Reconstitution · 24 Jul 2026 · 0 likes A 10 mg vial reconstituted three different ways: 1 mL diluent gives 10 mg/mL, 2 mL gives 5 mg/mL, 4 mL gives roughly 2.5 mg/mL. The arithmetic is the same; the…
-
Why the Start Here categories exist, and what they are not for Replied, post #27 · Start Here › Welcome · 23 Jul 2026 · 33 likes post #26 answers the question as asked. The question underneath it is different. Off-topic posts that do not belong here belong in the Lounge instead. You are not in…
-
Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Replied, post #72 · Evidence › Journal club · 22 Jul 2026 · 9 likes FLOW (N Engl J Med 2024): Semaglutide renal outcomes in type 2 diabetes and chronic kidney disease. Stopped early for efficacy. Component-by-component analysis is…
-
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #87 · Analytics › Impurities & related substances · 17 Jul 2026 · 3 likes Aggregates: multiples of the monomer mass. May not elute at all under a standard reversed-phase method. A species that does not come off the column does not appear in…
-
Retatrutide mass and identity: what a report should show Replied, post #16 · Compounds › Retatrutide · 13 Jul 2026 · 0 likes Phase 2 sample sizes are not adequate for safety characterisation of a novel triple agonist. Phase 3 is where that question gets answered. Using phase 2 results to make…
-
Follow-up: Prior authorisation: what the criteria usually require Replied, post #65 · Access › Insurance & coverage · 10 Jul 2026 · 0 likes Coverage for weight management versus diabetes: many formularies cover these compounds for type 2 diabetes but not for weight management. The indication matters and…
-
Substitution between formats during a shortage — what changed since Replied, post #5 · Access › Shortages · 9 Jul 2026 · 5 likes Coming back to post #3, because the follow-up matters more than the original answer. Practical note that does not fit anywhere else. Whatever you conclude from this…
-
Osteoarthritis and mechanical versus metabolic improvement — one year on Replied, post #6 · Clinical › Comorbidities · 9 Jul 2026 · 4 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
-
Revisiting: Protein density versus volume when you cannot eat much Replied, post #45 · Nutrition & Training › Protein & intake · 9 Jul 2026 · 0 likes Meeting protein targets on suppressed appetite: this is where the practical difficulty lies. Eating more protein when appetite is suppressed is genuinely hard.…
Maintains 1 document
- SUSTAIN 6 — trial digestReview due 3 Nov 2026